reports
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 03-Apr-2023 / 12:25 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trus...
Termination of Proposed Business Combination of Jounce Therapeutics, I...
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the ...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 30-March-2023 / 13:21 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 29-March-2023 / 13:22 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 28-March-2023 / 13:33 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra ...
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today ann...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 27-March-2023 / 13:18 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 24-March-2023 / 12:15 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 23-March-2023 / 11:09 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 22-March-2023 / 10:51 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 21-March-2023 / 10:51 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 20-March-2023 / 10:47 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 17-March-2023 / 12:07 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Jounce Therapeutics Announces Results from Pre-Planned Data Review of ...
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer are experiencing deep and durable resp...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 16-March-2023 / 11:54 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 15-March-2023 / 11:59 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
- Jonathan Moreland
WAFD WASHINGTON FEDERAL INC.
VLY VALLEY NATIONAL BANCORP
UMBF UMB FINANCIAL CORPORATION
SWX SOUTHWEST GAS HOLDINGS INC.
RRGB RED ROBIN GOURMET BURGERS INC.
RMAX RE/MAX HOLDINGS INC.
PSA PUBLIC STORAGE
PB PROSPERITY BANCSHARES INC.(R)
NSTG NANOSTRING TECHNOLOGIES
NMFC NEW MOUNTAIN FINANCE CORPORATION
MYE MYERS INDUSTRIES INC.
LKFN LAKELAND FINANCIAL CORPORATION
FMNB FARMERS NATIONAL BANC CORP.
FITB FIFTH THIRD BANCORP
FFIN FIRST FINANCIAL BANKSHARES INC
FCF FIRST COMMONWEALTH FINANCIAL CORPORATION
CUBI CUSTOMERS BANCORP INC.
CERS CERUS CORP.
CCNE CNB FINANCIAL CORP. (PENNSYLVANIA)
ATSG AIR TRANSPORT SERVICES GROUP INC.
WLKP WESTLAKE CHEMICAL PARTNERS LP
CFR CULLEN/FROST BANKERS INC.
SMMF SUMMIT FINANCIAL GROUP INC.
FBK FB FINANCIAL CORPORATION
JNCE JOUNCE THERAPEUTICS
GNTY GUARANTY BANCSHARES INC.
BY BYLINE BANCORP
CATC CAMBRIDGE BANCORP
MCB METROPOLITAN BANK HOLDING
MPB MID PENN BANCORP INC.
CCB COASTAL FINANCIAL
OPBK OP BANCORP
SCHW THE CHARLES SCHWAB CORPORATION
LARK LANDMARK BANCORP INC.
FNWB FIRST NORTHWEST BANCORP
MCBS METROCITY BANKSHARES
GRTX GALERA THERAPEUTICS
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
RILY B. RILEY FINANCIAL
VERA VERA THERAPEUTICS INC
TBBK THE BANCORP
FRST INC.
TNYA PRIMIS FINANCIAL CORP
TENAYA THERAPEUTICS INC
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Conc...
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirme...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc 14-March-2023 / 11:58 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the tr...
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc.
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc. 10-March-2023 / 13:20 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.